Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation

Journal of Biological Chemistry

Volumn 287, Issue 29, 2012, Pages 24821-24831

  Francescone, Ralph ^a   Scully, Steve ^a   Bentley, Brooke ^b   Yan, Wei ^b   Taylor, Sherry L ^c   Oh, Dennis ^c   Moral, Luis ^d   Shao, Rong ^a,b  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b Pioneer Valley Life Sciences Institute   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; BEVACIZUMAB; CELL LINES; FOCAL ADHESION KINASE; GENE KNOCK DOWN; GLIOBLASTOMA CELLS; GLIOBLASTOMAS; INTRACELLULAR SIGNALING; KINASE INHIBITORS; MICROVASCULAR; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR MECHANISM; NEUTRALIZING ANTIBODIES; PROTEIN ACTIVATION; THERAPEUTIC TARGETS; TUMOR CELLS; TUMOR DEVELOPMENT; VASCULAR FUNCTIONS; VASCULOGENESIS; VASCULOGENIC; XENOTRANSPLANTATION;

BLOOD VESSELS; CELL CULTURE; ENDOTHELIAL CELLS; GENES; PATIENT TREATMENT;

TUMORS;

BEVACIZUMAB; FOCAL ADHESION KINASE; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE 3; SHORT HAIRPIN RNA; SU 1498; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FLK 1 GENE; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR GENE; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CINNAMATES; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE; NEOVASCULARIZATION, PATHOLOGIC; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84863798167     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.334540     Document Type: Article

References (61)

1. Wen, P. Y, and Kesari, S. (2008) Malignant gliomas in adults. N. Engl. J. Med. 359, 492-507
2. Norden, A. D., Drappatz, J., and Wen, P. Y. (2009) Antiangiogenic therapies for high grade glioma. Nat. Rev. Neurosci. 5, 610-620
3. Nghiemphu, P. L., Liu, W., Lee, Y., Than, T., Graham, C., Lai, A., Green, R. M., Pope, W. B., Liau, L. M., Mischel, P. S., Nelson, S. F., Elashoff, R., and Cloughesy, T. F. (2009) Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72, 1217-1222
4. Bergers, G., and Hanahan, D. (2008) Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603
5. Ellis, L.M., and Hicklin, D.J. (2008) VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat. Rev. Cancer 8, 579-591
6. Verhoeff, J. J., van Tellingen, O., Claes, A., Stalpers, L. J., van Linde, M. E., Richel, D. J., Leenders, W. P., and van Furth, W. R. (2009) Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9, 444
7. Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., Park, J., Albert, P. S., and Fine, H. A. (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740-745
8. Ebos, J. M., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., and Kerbel, R. S. (2009) Accelerated metastasis after short term treatment with a potent inhibitor of tumor angiogenesis. See comment. Cancer Cell 15, 232-239
9. Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., and Casanovas, O. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. See comment. Cancer Cell 15, 220-231
10. Yue, W. Y., and Chen, Z. P. (2005) Does vasculogenic mimicry exist in astrocytoma? J. Histochem. Cytochem. 53, 997-1002
11. El Hallani, S., Boisselier, B., Peglion, F., Rousseau, A., Colin, C., Idbaih, A., Marie, Y., Mokhtari, K., Thomas, J. L., Eichmann, A., Delattre, J. Y., Maniotis, A. J., and Sanson, M. (2010) A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 133, 973-982
12. Liu, X. M., Zhang, Q. P., Mu, Y. G., Zhang, X. H., Sai, K., Pang, J. C., Ng, H. K., and Chen, Z. P. (2011) Clinical significance of vasculogenic mimicry in human gliomas. J. Neurooncol. 105, 173-179
13. Maniotis, A. J., Folberg, R., Hess, A., Seftor, E. A., Gardner, L. M., Pe'er, J., Trent, J. M., Meltzer, P. S., and Hendrix, M. J. (1999) Vascular channel formation by human melanoma cells in vivo and in vitro. Vasculogenic mimicry. Am. J. Pathol. 155, 739-752 (Pubitemid 29426820)
14. Folberg, R., and Maniotis, A.J. (2004) Vasculogenic mimicry. Acta Pathol. Microbiol. Immunol. Scand. 112, 508-525 (Pubitemid 39626057)
15. Ping, Y. F., and Bian, X. W. (2011) Concise review: Contribution of cancer stem cells to neovascularization. Stem Cells 29, 888-894
16. Chen, Y., Jing, Z., Luo, C., Zhuang, M., Xia, J., Chen, Z., and Wang, Y. (2012) Vasculogenic mimicry-potential target for glioblastoma therapy. An in vitro and in vivo study. Med. Oncol. 29, 324-331
17. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9-22 (Pubitemid 29038270)
18. Yancopoulos, G. D., Klagsbrun, M., and Folkman, J. (1998) Vasculogenesis, angiogenesis, and growth factors. Ephrins enter the fray at the border. Cell 93, 661-664 (Pubitemid 28257571)
19. Eichmann, A., Corbel, C., Nataf, V., Vaigot, P., Bréant, C., and Le Douarin, N. M. (1997) Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc. Natl. Acad. Sci. U.S.A. 94, 5141-5146 (Pubitemid 27214750)
20. Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, M. L., and Schuh, A. C. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66
21. Fong, G. H., Rossant, J., Gertsenstein, M., and Breitman, M. L. (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70
22. Sun, J., Wang, D. A., Jain, R. K., Carie, A., Paquette, S., Ennis, E., Blaskovich, M. A., Baldini, L., Coppola, D., Hamilton, A. D., and Sebti, S. M. (2005) Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene 24, 4701-4709 (Pubitemid 41032606)
23. Yan, W., Bentley, B., and Shao, R. (2008) Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis. The role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. Mol. Biol. Cell 19, 2278-2288
24. Yamashita, J., Itoh, H., Hirashima, M., Ogawa, M., Nishikawa, S., Yurugi, T., Naito, M., Nakao, K., and Nishikawa, S. (2000) Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 408, 92-96
25. + embryonic stem cell-derived population. Nature 453, 524-528
26. Taura, D., Sone, M., Homma, K., Oyamada, N., Takahashi, K., Tamura, N., Yamanaka, S., and Nakao, K. (2009) Induction and isolation of vascular cells from human-induced pluripotent stem cells. Brief report. Arterioscler. Thromb. Vasc. Biol. 29, 1100-1103
27. Shao, R., and Guo, X. (2004) Human microvascular endothelial cells immortalized with human telomerase catalytic protein. A model for the study of in vitro angiogenesis. Biochem. Biophys. Res. Commun. 321, 788-794 (Pubitemid 39044379)
28. Francescone, R. A., 3rd, Faibish, M., and Shao, R. (2011) A Matrigel-based tube formation assay to assess the vasculogenic activity of tumor cells. J. Vis. Exp. 55, 3040
29. Shao, R., Hamel, K., Petersen, L., Cao, Q. J., Arenas, R. B., Bigelow, C., Bentley, B., and Yan, W. (2009) YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28, 4456-4468
30. Paik, J. H., Skoura, A., Chae, S. S., Cowan, A. E., Han, D. K., Proia, R. L., and Hla, T. (2004) Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. Genes Dev. 18, 2392-2403 (Pubitemid 39304686)
31. Luo, Y., High, F. A., Epstein, J. A., and Radice, G. L. (2006) N-cadherin is required for neural crest remodeling of the cardiac outflow tract. Dev. Biol. 299, 517-528 (Pubitemid 44637279)
32. Folkman, J. (1971) Tumor angiogenesis. Therapeutic implications. N. Engl. J. Med. 285, 1182-1186
33. Hendrix, M.J., Seftor, E. A., Hess, A. R., and Seftor, R. E. (2003) Vasculogenic mimicry and tumor-cell plasticity. Lessons from melanoma. Nat. Rev. Cancer 3, 411-421 (Pubitemid 37328845)
34. Folberg, R., Arbieva, Z., Moses, J., Hayee, A., Sandal, T., Kadkol, S., Lin, A. Y., Valyi-Nagy, K., Setty, S., Leach, L., Chévez-Barrios, P., Larsen, P., Majumdar, D., Pe'er, J., and Maniotis, A. J. (2006) Tumor cell plasticity in uveal melanoma. Microenvironment directed dampening of the invasive and metastatic genotype and phenotype accompanies the generation of vasculogenic mimicry patterns. Am. J. Pathol. 169, 1376-1389 (Pubitemid 351194371)
35. di Tomaso, E., Capen, D., Haskell, A., Hart, J., Logie, J. J., Jain, R. K., McDonald, D. M., Jones, R., and Munn, L. L. (2005) Mosaic tumor vessels. Cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res. 65, 5740-5749 (Pubitemid 40911177)
36. Chang, Y. S., di Tomaso, E., McDonald, D. M., Jones, R., Jain, R. K., and Munn, L. L. (2000) Mosaic blood vessels in tumors. Frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. U.S.A. 97, 14608-14613 (Pubitemid 32016623)
37. Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue, H., Pastorino, S., Yang, M., Hoffman, R. M., Kesari, S., and Verma, I. M. (2011) Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 108, 4274-4280
38. Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K. E., Geber, A., Fligelman, B., Leversha, M., Brennan, C., and Tabar, V. (2010) Glioblastoma stem-like cells give rise to tumor endothelium. Nature 468, 829-833
39. Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., Maira, G., Parati, E. A., Stassi, G., Larocca, L. M., and De Maria, R. (2010) Tumor vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468, 824-828
40. Döme, B., Hendrix, M.J., Paku, S., Tová́ri, J., and Tímár, J. (2007) Alternative vascularization mechanisms in cancer. Pathology and therapeutic implications. Am. J. Pathol. 170, 1-15
41. Folberg, R., Hendrix, M. J., and Maniotis, A. J. (2000) Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 156, 361-381 (Pubitemid 30648785)
42. Wurmser, A. E., Nakashima, K., Summers, R. G., Toni, N., D'Amour, K. A., Lie, D. C., and Gage, F. H. (2004) Cell fusion-independent differentiation of neural stem cells to the endothelial lineage. Nature 430, 350-356 (Pubitemid 38937742)
43. Eliceiri, B. P. (2001) Integrin and growth factor receptor cross-talk. Circ. Res. 89, 1104-1110
44. Wijelath, E. S., Murray, J., Rahman, S., Patel, Y., Ishida, A., Strand, K., Aziz, S., Cardona, C., Hammond, W. P., Savidge, G. F., Rafii, S., and Sobel, M. (2002) Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ. Res. 91, 25-31 (Pubitemid 34778938)
45. Borges, E., Jan, Y., and Ruoslahti, E. (2000) Platelet-derived growth factor receptor β and vascular endothelial growth factor receptor 2 bind to the β3 integrin through its extracellular domain. J. Biol. Chem. 275, 39867-39873 (Pubitemid 32064606)
46. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., and Davidson, N. E. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676
47. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. See comment. N. Engl. J. Med. 350, 2335-2342 (Pubitemid 38702844)
48. Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., and Johnson, D. H. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (Pubitemid 44917502)
49. Manegold, C. (2008) Bevacizumab for the treatment of advanced nonsmall cell lung cancer. Expert Rev. Anticancer Ther. 8, 689-699
50. Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., Kesari, S., and Wen, P. Y. (2008) Bevacizumab for recurrent malignant gliomas. Efficacy, toxicity, and patterns of recurrence. Neurology 70, 779-787
51. Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., Shalinsky, D. R., Hu-Lowe, D. D., and McDonald, D. M. (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610-2621 (Pubitemid 44511625)
52. Keunen, O., Johansson, M., Oudin, A., Sanzey, M., Rahim, S. A., Fack, F., Thorsen, F., Taxt, T., Bartos, M., Jirik, R., Miletic, H., Wang, J., Stieber, D., Stuhr, L., Moen, I., Rygh, C. B., Bjerkvig, R., and Niclou, S. P. (2011) Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl. Acad. Sci. U.S.A. 108, 3749-3754
53. Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W. T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P. J., Zhu, M., Ancukiewicz, M., Mrugala, M. M., Plotkin, S., Drappatz, J., Louis, D. N., Ivy, P., Scadden, D. T., Benner, T., Loeffler, J. S., Wen, P. Y., and Jain, R. K. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (Pubitemid 46075199)
54. Kamoun, W. S., Ley, C. D., Farrar, C. T., Duyverman, A. M., Lahdenranta, J., Lacorre, D. A., Batchelor, T. T., di Tomaso, E., Duda, D. G., Munn, L. L., Fukumura, D., Sorensen, A. G., and Jain, R. K. (2009) Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol. 27, 2542-2552
55. Winkler, F., Kozin, S. V., Tong, R. T., Chae, S. S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., Munn, L. L., and Jain, R. K. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation. Role of oxygenation, angiopoietin- 1, and matrix metalloproteinases. Cancer Cell 6, 553-563 (Pubitemid 40017699)
56. Timke, C., Zieher, H., Roth, A., Hauser, K., Lipson, K. E., Weber, K. J., Debus, J., Abdollahi, A., and Huber, P. E. (2008) Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin. Cancer Res. 14, 2210-2219 (Pubitemid 351551134)
57. Kozin, S. V., Boucher, Y., Hicklin, D. J., Bohlen, P., Jain, R. K., and Suit, H. D. (2001) Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long term control of human tumor xenografts. Cancer Res. 61, 39-44 (Pubitemid 32095696)
58. Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N. M., Pastorino, S., Purow, B. W., Christopher, N., Zhang, W., Park, J. K., and Fine, H. A. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391-403 (Pubitemid 43668737)
59. Basu, G. D., Liang, W. S., Stephan, D. A., Wegener, L. T., Conley, C. R., Pockaj, B. A., and Mukherjee, P. (2006) A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res. 8, R69
60. Liu, C., Huang, H., Doñate, F., Dickinson, C., Santucci, R., El-Sheikh, A., Vessella, R., and Edgington, T. S. (2002) Prostate-specific membrane antigen-directed selective thrombotic infarction of tumors. Cancer Res. 62, 5470-5475
61. Sood, A. K., Fletcher, M. S., Zahn, C. M., Gruman, L. M., Coffin, J. E., Seftor, E. A., and Hendrix, M. J. (2002) The clinical significance of tumor cell-lined vasculature in ovarian carcinoma. Implications for anti-vasculogenic therapy. Canc. Biol. Ther. 1, 661-664